{'fraction_non_alphanumeric': 0.03213242453748783, 'fraction_numerical': 0.021421616358325218, 'mean_word_length': 5.425, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
42A: EFFECT OF DONOR-RECIPIENT CHIMERIC CELLS THERAPY ON T REGULATORY CELL POPULATION AND TOLEROGENIC FACTORS GENE EXPRESSION IN FACE ALLOGRAFT MODEL

Methods: Nineteen hemiface transplantations were carried out in 5 groups. Group 1, 2isotransplants were performed between Lewis rats (RT1l) with or without treatment. Hemiface allotransplantations were performed between ACI (RT1a) donors and Lewis (RT1l) recipients. Recipients were treated either with continuous CsA protocolgroup 3 or anti-TCR/CsA protocol for 7 days only group 4. Short-term immunosuppressive protocol was augmented with 4x106 in vivo created donor-recipient chimeric cells (DRCC) group 5. Blood samples and skin biopsies from donor face allograft and adjacent recipient skin were harvested at various posttransplant time points. Gene expression of tolerogenic cytokines (Il-10, Tgf) and factor FoxP3 was evaluated in skin biopsies using Taqman® real-time PCR. Flow cytometry analysis was used to determine changes in T regulatory cell population (CD4/25).